menu
    • menu
    [{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Ligand Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Ligand Research, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Ligand Research, LLC"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Ligand Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Ligand Research, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Ligand Research, LLC"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Midas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Midas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, San Diego \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Diego \/ Pfizer Inc"},{"orgOrder":0,"company":"University of California","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"||Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ferrer Internacional \/ CNIC","highestDevelopmentStatusID":"15","companyTruncated":"Ferrer Internacional \/ CNIC"}]

    Find Clinical Drug Pipeline Developments & Deals for Ramipril

    Menu

    Ramipril

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One Hi...

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Coronary Artery Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2017

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2010

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Condit...

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2010

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ramipril 10 mg/Day Prevention

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atherosclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2010

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharmtechnology

                            Belarus arrow
                            Luxepack
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Ligand Research, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunt...

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Ligand Research, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ferrer Internacional

                            Germany arrow
                            Luxepack
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aspirin,Ramipril,Simvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : CNIC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction

                            Details : The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.

                            Product Name : Polypill

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2022

                            Lead Product(s) : Aspirin,Ramipril,Simvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : CNIC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmtechnology

                            Belarus arrow
                            Luxepack
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Ligand Research, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditi...

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 29, 2022

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Ligand Research, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of California

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UC San Diego to Assess Hypertension Drug Ramipril for Covid-19

                            Details : Ramipril will be assessed for its potential to decrease the severity of Covid-19, lower intensive care unit admission rates, mechanical ventilators use, and all-cause mortality.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 01, 2020

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of California, San Diego

                            Country arrow
                            Luxepack
                            Not Confirmed

                            University of California, San Diego

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ramipril for the Treatment of COVID-19

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 28, 2020

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Midas Pharma

                            Germany arrow
                            Luxepack
                            Not Confirmed

                            Midas Pharma

                            Germany arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-drug-interaction Study of Ramipril, Amlodipine and Atorvastatin

                            Details : Ramipril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2020

                            Lead Product(s) : Ramipril

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth